| Outcome Measures: |
Primary: Change in Glycemic variability, Continuous glucose monitoring system (CGMS) during 48 hours (24h before and 24 after the submaximal exercise test)., Baseline and 12 weeks | Secondary: Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP), Cardiac output (Q) and the Stroke Volume (SV)and blood pressure (BP) will be measured before the sub-maximal tests, 10% below the second threshold and every 2 minutes of recovery., Each 2 minutes during exercise and until 60 min post in baseline and 12 weeks | Other: Change in Flow Mediated Dilatation (FMD), This analysis will be performed by a high-resolution ultrasound of the brachial artery (doppler vascular), which characterizes the Flow Mediated Dilatation (FMD), which is expressed by changes in basal diameter in response to the increased flow and Nitroglycerin (NTG), which will be applied in a single dose (0.4 mg) as a sublingual spray., Baseline and 12 weeks|Change in Blood pressure variability, Blood Pressure Monitoring Sensor (BPMS)which will be programmed to automatically measuring the blood pressure every 15 minutes during the day (06:00 to 22:00 h), and every 20 minutes during the night (22:00 to 6:00 h., Baseline and 12 weeks|Change in Plasma glucagon concentration on exercise, EDTA Vacutainer tubes of 10 ml will be used to perform the blood tests and they will be stored at -20º to send them to the Molecular and Proteins Analysis Unit after buying specific kit., -1h, 0, 15min, 30 min (end), 60min post exercise in baseline and 12 weeks|Change in Oxidative stress (F2 isoprostane 8-iso prostaglandin F2α);, The 24-hour urinary samples will be collected at visit 1 and 4 to evaluate the oxidative stress. Free 8-iso PGF2α that is most frequently measured F2 isoprostane in body fluids., Baseline and 12 weeks.
|
